About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
PEPFAR Watch
Blog
Our Impact
Take Action
Do something now
DONATE
Access to Medicines
Access to Medicines
TRIPS-Compliant Alternatives for Overcoming Intellectual Property Barriers to CO...
Access to Medicines
Letter to ViiV re CAB-LA for PrEP
Access to Medicines
BMJ Global Health: A pandemic treaty for equitable global access to medical coun...
Access to Medicines
Letter to Pres. Biden on COVID19 Global Summit May 2022
Access to Medicines
Amicus Brief on Human Rights Principles and TRIPS-Compliant Interpretation to th...
Access to Medicines
Policy Brief: Community-Based COVID-19 Test-and-Treat (April 2022)
Access to Medicines
Community-Based Test-and-Treat
Access to Medicines
To Save Lives, a COVID Intellectual Property Waiver Must Cover Medicines and Oth...
Access to Medicines
Request of Least Developed Countries for Extension of Transition Period
Access to Medicines
Policy Brief: Third-Way Proposals from Big Pharma and the WTO are the Same-Old W...
Access to Medicines
COVID-19 Emergency Supplemental Spending and the U.S. Global AIDS Response
Access to Medicines
Webinar: How YOU Can Increase COVID-19 Vaccine Access Worldwide
Access to Medicines
Letter to CEOs of Pharma Companies Producing COVID19 Vaccines
Access to Medicines
CSO Letter to Gavi Board
Access to Medicines
Health GAP’s Testimony for U.S. House Committee on Oversight and Reform
Access to Medicines
Policy Brief: Dolutegravir in Southern & Eastern Africa and the Right to Ch...
